Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arjen R. Mensenkamp is active.

Publication


Featured researches published by Arjen R. Mensenkamp.


Nature Genetics | 2003

Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders.

Bethan Jones; Emma L. Jones; Stephanie A. Bonney; Hetal Patel; Arjen R. Mensenkamp; Sophie Eichenbaum-Voline; Mats Rudling; Urban Myrdal; Grazia Annesi; Sandhia Naik; Nigel Meadows; Aldo Quattrone; Suhail A. Islam; Rossitza P. Naoumova; Bo Angelin; R. Infante; Emile Levy; Claude C. Roy; Paul S. Freemont; James Scott; Carol C. Shoulders

Dietary fat is an important source of nutrition. Here we identify eight mutations in SARA2 that are associated with three severe disorders of fat malabsorption. The Sar1 family of proteins initiates the intracellular transport of proteins in COPII (coat protein)-coated vesicles. Our data suggest that chylomicrons, which vastly exceed the size of typical COPII vesicles, are selectively recruited by the COPII machinery for transport through the secretory pathways of the cell.


Clinical Cancer Research | 2012

MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.

Nelly Burnichon; Alberto Cascón; Francesca Schiavi; NicolePaes Morales; Iñaki Comino-Méndez; Nasséra Abermil; Lucía Inglada-Pérez; Aguirre A. de Cubas; Laurence Amar; Marta Barontini; Sandra Bernaldo De Quiroś; Jérôome Bertherat; Yves Jean Bignon; Marinus J. Blok; Sara Bobisse; Salud Borrego; Maurizio Castellano; Philippe Chanson; María Dolores Chiara; Eleonora P. M. Corssmit; Mara Giacchè; Ronald R. de Krijger; Tonino Ercolino; Xavier Girerd; Encarna B. Gomez-Garcia; Álvaro Gómez-Graña; Isabelle Guilhem; Frederik J. Hes; Emiliano Honrado; Esther Korpershoek

Purpose: Pheochromocytomas (PCC) and paragangliomas (PGL) are genetically heterogeneous neural crest–derived neoplasms. Recently we identified germline mutations in a new tumor suppressor susceptibility gene, MAX (MYC-associated factor X), which predisposes carriers to PCC. How MAX mutations contribute to PCC/PGL and associated phenotypes remain unclear. This study aimed to examine the prevalence and associated phenotypic features of germline and somatic MAX mutations in PCC/PGL. Design: We sequenced MAX in 1,694 patients with PCC or PGL (without mutations in other major susceptibility genes) from 17 independent referral centers. We screened for large deletions/duplications in 1,535 patients using a multiplex PCR-based method. Somatic mutations were searched for in tumors from an additional 245 patients. The frequency and type of MAX mutation was assessed overall and by clinical characteristics. Results: Sixteen MAX pathogenic mutations were identified in 23 index patients. All had adrenal tumors, including 13 bilateral or multiple PCCs within the same gland (P < 0.001), 15.8% developed additional tumors at thoracoabdominal sites, and 37% had familial antecedents. Age at diagnosis was lower (P = 0.001) in MAX mutation carriers compared with nonmutated cases. Two patients (10.5%) developed metastatic disease. A mutation affecting MAX was found in five tumors, four of them confirmed as somatic (1.65%). MAX tumors were characterized by substantial increases in normetanephrine, associated with normal or minor increases in metanephrine. Conclusions: Germline mutations in MAX are responsible for 1.12% of PCC/PGL in patients without evidence of other known mutations and should be considered in the genetic work-up of these patients. Clin Cancer Res; 18(10); 2828–37. ©2012 AACR.


Human Mutation | 2013

A Post-Hoc Comparison of the Utility of Sanger Sequencing and Exome Sequencing for the Diagnosis of Heterogeneous Diseases

Kornelia Neveling; Ilse Feenstra; Christian Gilissen; Lies H. Hoefsloot; Erik-Jan Kamsteeg; Arjen R. Mensenkamp; Richard J. Rodenburg; Helger G. Yntema; Liesbeth Spruijt; Sascha Vermeer; Tuula Rinne; Koen L. van Gassen; Danielle Bodmer; Dorien Lugtenberg; Rick de Reuver; Wendy Buijsman; Ronny Derks; Nienke Wieskamp; Bert van den Heuvel; Marjolijn J. L. Ligtenberg; Hannie Kremer; David A. Koolen; Bart P. van de Warrenburg; Frans P.M. Cremers; Carlo Marcelis; Jan A.M. Smeitink; Saskia B. Wortmann; Wendy A. G. van Zelst-Stams; Joris A. Veltman; Han G. Brunner

The advent of massive parallel sequencing is rapidly changing the strategies employed for the genetic diagnosis and research of rare diseases that involve a large number of genes. So far it is not clear whether these approaches perform significantly better than conventional single gene testing as requested by clinicians. The current yield of this traditional diagnostic approach depends on a complex of factors that include gene‐specific phenotype traits, and the relative frequency of the involvement of specific genes. To gauge the impact of the paradigm shift that is occurring in molecular diagnostics, we assessed traditional Sanger‐based sequencing (in 2011) and exome sequencing followed by targeted bioinformatics analysis (in 2012) for five different conditions that are highly heterogeneous, and for which our center provides molecular diagnosis. We find that exome sequencing has a much higher diagnostic yield than Sanger sequencing for deafness, blindness, mitochondrial disease, and movement disorders. For microsatellite‐stable colorectal cancer, this was low under both strategies. Even if all genes that could have been ordered by physicians had been tested, the larger number of genes captured by the exome would still have led to a clearly superior diagnostic yield at a fraction of the cost.


Gastroenterology | 2014

Somatic Mutations in MLH1 and MSH2 Are a Frequent Cause of Mismatch-Repair Deficiency in Lynch Syndrome-Like Tumors

Arjen R. Mensenkamp; Ingrid P. Vogelaar; Wendy A.G. van Zelst–Stams; Monique Goossens; Hicham Ouchene; Sandra J B Cornelissen; Michael P. Kwint; Nicoline Hoogerbrugge; Iris D. Nagtegaal; Marjolijn J. L. Ligtenberg

Lynch syndrome is caused by germline mutations in the mismatch repair (MMR) genes. Tumors are characterized by microsatellite instability (MSI). However, a considerable number of MSI-positive tumors have no known molecular mechanism of development. By using Sanger and ion semiconductor sequencing, 25 MSI-positive tumors were screened for somatic mutations and loss of heterozygosity in mutL homolog 1 (MLH1) and mutS homolog 2 (MSH2). In 13 of 25 tumors (8 MLH1-deficient and 5 MSH2-deficient tumors), we identified 2 somatic mutations in these genes. We conclude that 2 acquired events explain the MMR-deficiency in more than 50% of the MMR-deficient tumors without causal germline mutations or promoter methylation.


Journal of Biological Chemistry | 2006

PACSINs Bind to the TRPV4 Cation Channel PACSIN 3 MODULATES THE SUBCELLULAR LOCALIZATION OF TRPV4

Math P. Cuajungco; Christian Grimm; Kazuo Oshima; Dieter D'hoedt; Bernd Nilius; Arjen R. Mensenkamp; René J. M. Bindels; Markus Plomann; Stefan Heller

TRPV4 is a cation channel that responds to a variety of stimuli including mechanical forces, temperature, and ligand binding. We set out to identify TRPV4-interacting proteins by performing yeast two-hybrid screens, and we isolated with the avian TRPV4 amino terminus the chicken orthologues of mammalian PACSINs 1 and 3. The PACSINs are a protein family consisting of three members that have been implicated in synaptic vesicular membrane trafficking and regulation of dynamin-mediated endocytotic processes. In biochemical interaction assays we found that all three murine PACSIN isoforms can bind to the amino terminus of rodent TRPV4. No member of the PACSIN protein family was able to biochemically interact with TRPV1 and TRPV2. Co-expression of PACSIN 3, but not PACSINs 1 and 2, shifted the ratio of plasma membrane-associated versus cytosolic TRPV4 toward an apparent increase of plasma membrane-associated TRPV4 protein. A similar shift was also observable when we blocked dynamin-mediated endocytotic processes, suggesting that PACSIN 3 specifically affects the endocytosis of TRPV4, thereby modulating the subcellular localization of the ion channel. Mutational analysis shows that the interaction of the two proteins requires both a TRPV4-specific proline-rich domain upstream of the ankyrin repeats of the channel and the carboxyl-terminal Src homology 3 domain of PACSIN 3. Such a functional interaction could be important in cell types that show distribution of both proteins to the same subcellular regions such as renal tubule cells where the proteins are associated with the luminal plasma membrane.


Molecular and Cellular Biology | 2006

Direct Interaction with Rab11a Targets the Epithelial Ca2+ Channels TRPV5 and TRPV6 to the Plasma Membrane

Stan F. J. van de Graaf; Qing Chang; Arjen R. Mensenkamp; Joost G. J. Hoenderop; René J. M. Bindels

ABSTRACT TRPV5 and TRPV6 are the most Ca2+-selective members of the transient receptor potential (TRP) family of cation channels and play a pivotal role in the maintenance of Ca2+ balance in the body. However, little is known about the mechanisms controlling the plasma membrane abundance of these channels to regulate epithelial Ca2+ transport. In this study, we demonstrated the direct and specific interaction of GDP-bound Rab11a with TRPV5 and TRPV6. Rab11a colocalized with TRPV5 and TRPV6 in vesicular structures underlying the apical plasma membrane of Ca2+-transporting epithelial cells. This GTPase recognized a conserved stretch in the carboxyl terminus of TRPV5 that is essential for channel trafficking. Furthermore, coexpression of GDP-locked Rab11a with TRPV5 or TRPV6 resulted in significantly decreased Ca2+ uptake, caused by diminished channel cell surface expression. Together, our data demonstrated the important role of Rab11a in the trafficking of TRPV5 and TRPV6. Rab11a exerts this function in a novel fashion, since it operates via direct cargo interaction while in the GDP-bound configuration.


The EMBO Journal | 2006

Calbindin-D28K dynamically controls TRPV5-mediated Ca2+ transport

Tim T. Lambers; Frank Mahieu; Elena Oancea; Louis Hoofd; Frank de Lange; Arjen R. Mensenkamp; Thomas Voets; Bernd Nilius; David E. Clapham; Joost G.J. Hoenderop; René J. M. Bindels

In Ca2+‐transporting epithelia, calbindin‐D28K (CaBP28K) facilitates Ca2+ diffusion from the luminal Ca2+ entry side of the cell to the basolateral side, where Ca2+ is extruded into the extracellular compartment. Simultaneously, CaBP28K provides protection against toxic high Ca2+ levels by buffering the cytosolic Ca2+ concentration ([Ca2+]i) during high Ca2+ influx. CaBP28K consistently colocalizes with the epithelial Ca2+ channel TRPV5, which constitutes the apical entry step in renal Ca2+‐transporting epithelial cells. Here, we demonstrate using protein‐binding analysis, subcellular fractionation and evanescent‐field microscopy that CaBP28K translocates towards the plasma membrane and directly associates with TRPV5 at a low [Ca2+]i. 45Ca2+ uptake measurements, electrophysiological recordings and transcellular Ca2+ transport assays of lentivirus‐infected primary rabbit connecting tubule/distal convolute tubule cells revealed that associated CaBP28K tightly buffers the flux of Ca2+ entering the cell via TRPV5, facilitating high Ca2+ transport rates by preventing channel inactivation. In summary, CaBP28K acts in Ca2+‐transporting epithelia as a dynamic Ca2+ buffer, regulating [Ca2+] in close vicinity to the TRPV5 pore by direct association with the channel.


Clinical Genetics | 2011

Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis

D.L. Smit; Arjen R. Mensenkamp; Sadhanna Badeloe; Martijn H. Breuning; Marleen Simon; K.Y. van Spaendonck; Cora M. Aalfs; Jan G. Post; Susan Shanley; Ingrid P. C. Krapels; Lies H. Hoefsloot; R. J. A. van Moorselaar; Theo M. Starink; Jean-Pierre Bayley; Josef Frank; M.A.M. van Steensel; Fred H. Menko

Smit DL, Mensenkamp AR, Badeloe S, Breuning MH, Simon MEH, van Spaendonck KY, Aalfs CM, Post JG, Shanley S, Krapels IPC, Hoefsloot LH, van Moorselaar RJA, Starink TM, Bayley J‐P, Frank J, van Steensel MAM, Menko FH. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis.


Journal of Clinical Oncology | 2015

Lynch Syndrome Caused by Germline PMS2 Mutations: Delineating the Cancer Risk

Sanne W. ten Broeke; Richard Brohet; Carli C. Tops; Heleen M. van der Klift; M.E. Velthuizen; Inge Bernstein; Gabriel Capellá Munar; Encarna Gomez Garcia; Nicoline Hoogerbrugge; Tom G. W. Letteboer; Fred F. Menko; Annika A. Lindblom; Arjen R. Mensenkamp; Pål Møller; Theo A. van Os; Nils Rahner; Bert Redeker; Rolf H. Sijmons; Liesbeth Spruijt; Manon Suerink; Yvonne J. Vos; Anja Wagner; Frederik J. Hes; Hans Vasen; Maartje Nielsen; Juul T. Wijnen

PURPOSE The clinical consequences of PMS2 germline mutations are poorly understood compared with other Lynch-associated mismatch repair gene (MMR) mutations. The aim of this European cohort study was to define the cancer risk faced by PMS2 mutation carriers. METHODS Data were collected from 98 PMS2 families ascertained from family cancer clinics that included a total of 2,548 family members and 377 proven mutation carriers. To adjust for potential ascertainment bias, a modified segregation analysis model was used to calculate colorectal cancer (CRC) and endometrial cancer (EC) risks. Standardized incidence ratios (SIRs) were calculated to estimate risks for other Lynch syndrome-associated cancers. RESULTS The cumulative risk (CR) of CRC for male mutation carriers by age 70 years was 19%. The CR among female carriers was 11% for CRC and 12% for EC. The mean age of CRC development was 52 years, and there was a significant difference in mean age of CRC between the probands (mean, 47 years; range, 26 to 68 years) and other family members with a PMS2 mutation (mean, 58 years; range, 31 to 86 years; P < .001). Significant SIRs were observed for cancers of the small bowel, ovaries, breast, and renal pelvis. CONCLUSION CRC and EC risks were found to be markedly lower than those previously reported for the other MMR. However, these risks embody the isolated risk of carrying a PMS2 mutation, and it should be noted that we observed a substantial variation in cancer phenotype within and between families, suggesting the influence of genetic modifiers and lifestyle factors on cancer risks.


Current Opinion in Nephrology and Hypertension | 2006

Recent advances in renal tubular calcium reabsorption.

Arjen R. Mensenkamp; Joost G. J. Hoenderop; René J. M. Bindels

Purpose of reviewKnowledge of renal Ca2+ reabsorption has evolved greatly in recent years. This review focuses on two recent discoveries concerning passive and active Ca2+ reabsorption. Recent findingsThe thiazide diuretics are known for their hypocalciuric effect. Recently, it has been demonstrated that TRPV5-knockout mice, in which active Ca2+ reabsorption in the distal convoluted tubule is completely abolished, show the same sensitivity towards thiazides as wild-type mice. This indicates that thiazide affects Ca2+ reabsorption indirectly via contraction of the extracellular volume, independent of active Ca2+ reabsorption in the distal convoluted tubule, thereby increasing passive paracellular Ca2+ transport in the proximal tubule. Moreover, the antiaging hormone Klotho regulates Ca2+ reabsorption in the distal convoluted tubule via a novel molecular mechanism. Klotho stabilizes the TRPV5 Ca2+ channel in the plasma membrane by deglycosylation of the protein. SummaryBy showing that thiazide-induced hypercalciuria is due to increased passive Ca2+ reabsorption in the proximal tubule, a long-standing issue has been solved, underlining the importance of proximal paracellular Ca2+ reabsorption. Moreover, the molecular mechanism by which the antiaging hormone Klotho regulates TRPV5 activity may prove to be generally applicable in Klotho-mediated prevention of aging.

Collaboration


Dive into the Arjen R. Mensenkamp's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Folkert Kuipers

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Liesbeth Spruijt

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar

Anja Wagner

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fred H. Menko

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Carli M. J. Tops

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge